Debio 1454/M

Indicaton

GI disorders

Therapeutic indications

Infectious disease

Type of product

Small molecule

Table

Phase

Discovery
Partnering status

Partnered
Partner

Takeda

You may also be interested in

Debio 4028

Infectious diseases Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.

MV-003 Dysbiosis

Dysbiosis ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.

MV-001 Clostridioides Difficile

Clostridioides Difficile ApyraVax is suitable for continuous dosing, exploits the already marketed and safe Salmonella Ty21a vaccine strain (Vivotif®) and induces high-affinity secretory IgAs that ensure protection from CDI.